ACM
VTGN icon

ADAR1 Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

ADAR1 Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-120,000
Closed -$79.4K – 342
2025
Q4 		$79.4K Buy
+120,000
New +$433K 0.01% 259

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management's VTGN Position: Q2 2026 in Review

ADAR1 Capital Management reduced its VistaGen Therapeutics (VTGN) stake by 53% in Q2 2026, selling an estimated $241K and leaving 351,141 shares worth $79.4K. The position accounts for ﹤0.01% of the portfolio, ranked #266.

ADAR1 Capital Management first reported a position in VTGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.26M in Q4 2023. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • ADAR1 Capital Management held 351,141 shares of VistaGen Therapeutics worth $79.4K as of Q2 2026.
  • ADAR1 Capital Management sold 400,000 VistaGen Therapeutics shares in Q2 2026, an estimated $241K.
  • VistaGen Therapeutics made up ﹤0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #266 holding.
  • ADAR1 Capital Management first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • ADAR1 Capital Management's VistaGen Therapeutics position peaked at $1.26M in Q4 2023.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.